IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven TumorsPRNewsWire • 03/14/22
IDEAYA Biosciences Announces Investor Webcast to Report Interim IDE397 Phase 1 Clinical Data and Corporate UpdatePRNewsWire • 03/08/22
IDEAYA Advances First-in-Class PARG Development Candidate, IDE161, into IND-Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide LicensePRNewsWire • 01/31/22
IDEAYA Biosciences Announces Corporate and Portfolio Update for J.P. Morgan 40th Annual Healthcare ConferencePRNewsWire • 01/10/22
IDEAYA Biosciences Announces Acquisition of Proprietary INQUIRE™ Chemical Library to Enhance Synthetic Lethality Drug Discovery PlatformPRNewsWire • 01/05/22
IDEAYA Biosciences Appoints Dr. Frank McCormick as Chair of Scientific Advisory BoardPRNewsWire • 01/04/22
IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal MelanomaPRNewsWire • 12/07/21
IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal MelanomaPRNewsWire • 11/29/21
IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business UpdatePRNewsWire • 11/15/21
Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to DeclineZacks Investment Research • 11/04/21
IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business UpdatePRNewsWire • 08/10/21
IDEAYA Biosciences to Participate in Panel Discussion at 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021PRNewsWire • 08/02/21
Forensic Value Stock Selections: Top Positive And Negative Scoring Stocks For Mid-Year 2021Seeking Alpha • 07/06/21
IDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib CombinationPRNewsWire • 06/28/21